Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Jun 13, 2023
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Purchase
Common Stock
2023-06-09$3.42/sh+511$1,748→ 1,262 total
Footnotes (1)
- [F1]These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan.